Lp. Boulet et al., INFLUENCE OF SALMETEROL ON CHRONIC AND ALLERGEN-INDUCED AIRWAY INFLAMMATION IN MILD ALLERGIC-ASTHMA - A PILOT-STUDY, Current therapeutic research, 58(4), 1997, pp. 240-259
Citations number
47
Categorie Soggetti
Pharmacology & Pharmacy","Medicine, Research & Experimental
Salmeterol xinafoate, a potent, long-acting, selective beta(2)-agonist
, inhibits allergen-induced asthmatic responses. To evaluate if this b
ronchoprotection was also associated with anti-inflammatory effects, m
ild asthmatic patients presenting a dual asthmatic response to allerge
ns were randomized in a double-masked, placebo-controlled, parallel-gr
oup study to take either salmeterol 50 mu g twice daily (n = 7) or pla
cebo (n = 6) for 2 months. At the end of the treatment period, airway
inflammation was assessed by bronchoalveolar lavage and bronchial biop
sies, both before and after allergen challenge. After treatment, aller
gen-induced responses were decreased in the salmeterol group and, to a
lesser degree, in the placebo group. Postallergen and preallergen cha
llenge, lavage total, and differential cell counts mere similar in the
two groups. Before allergen challenge, bronchial biopsies of both gro
ups indicated extensive airway inflammation with similar total inflamm
atory cell counts but with a higher percentage of epithelial desquamat
ion in the salmeterol group. The allergen challenge did not modify the
inflammatory variables measured except for an increase in eosinophil
counts in connective tissue. Comparison of the postchallenge data of t
he two groups showed that counts of AA1-, HLA-DR-, and CD45ro-positive
cells were reduced in the salmeterol group. When prechallenge and pos
tchallenge data were pooled to compare the two treatments, the salmete
rol group had lower numbers of CD3-, CD25-, HLA-DR-, AA1-, CD45-, and
CD45ro-positive cells. In conclusion, these results confirmed the bron
chodilator and bronchoprotective effects of salmeterol. They also sugg
ested that; even though salmeterol did not modify lavage and overall b
ronchial biopsy cellular infiltrate, the drug apparently reduced expre
ssion of some bronchial mucosa activation cell markers. This study, ho
wever, was mainly exploratory, and the reproducibility and clinical si
gnificance of these observations require further clarification.